276 related articles for article (PubMed ID: 36671402)
21. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
Zhang YN; Zhang QY; Li XD; Xiong J; Xiao SQ; Wang Z; Zhang ZR; Deng CL; Yang XL; Wei HP; Yuan ZM; Ye HQ; Zhang B
Emerg Microbes Infect; 2020 Dec; 9(1):1170-1173. PubMed ID: 32432977
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
Kinobe RT; Owens L
Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
[TBL] [Abstract][Full Text] [Related]
23. Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines.
Sandenon Seteyen AL; Girard-Valenciennes E; Septembre-Malaterre A; Gasque P; Guiraud P; Sélambarom J
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014321
[TBL] [Abstract][Full Text] [Related]
24. Diverse isoquinolines with anti-inflammatory and analgesic bioactivities from Hypecoum erectum.
Yuan HL; Zhao YL; Qin XJ; Liu YP; Yang XW; Luo XD
J Ethnopharmacol; 2021 Apr; 270():113811. PubMed ID: 33444717
[TBL] [Abstract][Full Text] [Related]
25. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
26. [Progress of antibacterial activity and antibacterial mechanism of isoquinoline alkaloids].
Cao P; Zhang ZW; Leng DJ; Li XY; Li Y
Zhongguo Zhong Yao Za Zhi; 2016 Jul; 41(14):2600-2606. PubMed ID: 28905593
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Malekmohammad K; Rafieian-Kopaei M
Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
[TBL] [Abstract][Full Text] [Related]
28. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.
Fuzimoto AD
J Integr Med; 2021 Sep; 19(5):375-388. PubMed ID: 34479848
[TBL] [Abstract][Full Text] [Related]
29. In vitro anti-influenza virus activity of isoquinoline alkaloids from thalictrum species.
Serkedjieva J; Velcheva M
Planta Med; 2003 Feb; 69(2):153-4. PubMed ID: 12624821
[TBL] [Abstract][Full Text] [Related]
30. Alkaloids: Therapeutic Potential against Human Coronaviruses.
Fielding BC; da Silva Maia Bezerra Filho C; Ismail NSM; Sousa DP
Molecules; 2020 Nov; 25(23):. PubMed ID: 33255253
[TBL] [Abstract][Full Text] [Related]
31. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
32. [Progress in the study of antiviral activity of cepharanthine against SARS-CoV-2].
Fan H; Liu K; Hong B; He S; Han P; Li M; Wang S; Tong Y
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):955-956. PubMed ID: 35790449
[TBL] [Abstract][Full Text] [Related]
33. Marine Brominated Tyrosine Alkaloids as Promising Inhibitors of SARS-CoV-2.
El-Demerdash A; Hassan A; Abd El-Aziz TM; Stockand JD; Arafa RK
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684755
[TBL] [Abstract][Full Text] [Related]
34. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
35. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
36. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
37. Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV-2.
Manna S; Chowdhury T; Baindara P; Mandal SM
Curr Protein Pept Sci; 2020; 21(10):938-947. PubMed ID: 32901582
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial activity of some isoquinoline alkaloids.
Abbasoglu U; Sener B; Günay Y; Temizer H
Arch Pharm (Weinheim); 1991 Jun; 324(6):379-80. PubMed ID: 1763949
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in the Discovery of Antiviral Metabolites from Fungi.
Deshmukh SK; Agrawal S; Gupta MK; Patidar RK; Ranjan N
Curr Pharm Biotechnol; 2022; 23(4):495-537. PubMed ID: 34132180
[TBL] [Abstract][Full Text] [Related]
40. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
